The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect
cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the …

Diabetes is one of the fastest growing diseases worldwide, projected to affect 693 million
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …

The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, based …

Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Diabetic nephropathy (DN) is one of the most severe complications of diabetes. However,
due to its complex pathological mechanisms, no effective therapeutic methods (other than …